Abstract | BACKGROUND: PURPOSE: We investigated the effects of candesartan, an angiotensin type II receptor blocker, on the diabetes-induced atrial structural change. METHODS AND RESULTS: CONCLUSIONS:
Candesartan reduced CTGF expression and attenuated the fibrosis in diabetic rat atria. These results implied the protective effects of candesartan on diabetes-related atrial arrhythmias.
|
Authors | Takeshi Kato, Takeshi Yamashita, Akiko Sekiguchi, Takayuki Tsuneda, Kouichi Sagara, Masayuki Takamura, Shuichi Kaneko, Tadanori Aizawa, Long-Tai Fu |
Journal | Journal of cardiology
(J Cardiol)
Vol. 58
Issue 2
Pg. 131-6
(Sep 2011)
ISSN: 1876-4738 [Electronic] Netherlands |
PMID | 21802905
(Publication Type: Journal Article)
|
Copyright | Copyright © 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. |
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Benzimidazoles
- Biphenyl Compounds
- CCN2 protein, human
- Receptor for Advanced Glycation End Products
- Tetrazoles
- Connective Tissue Growth Factor
- candesartan
|
Topics |
- Angiotensin II Type 1 Receptor Blockers
(administration & dosage, pharmacology, therapeutic use)
- Animals
- Arrhythmias, Cardiac
(prevention & control)
- Benzimidazoles
(administration & dosage, pharmacology, therapeutic use)
- Biphenyl Compounds
- Connective Tissue Growth Factor
(metabolism)
- Diabetes Mellitus, Experimental
(drug therapy, pathology)
- Female
- Fibrosis
- Heart Atria
(metabolism, pathology)
- Rats
- Rats, Sprague-Dawley
- Receptor for Advanced Glycation End Products
(metabolism)
- Tetrazoles
(administration & dosage, pharmacology, therapeutic use)
|